The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial

Atherosclerosis

Volumn 147, Issue 1, 1999, Pages 193-197

  Törnwall, Markareetta E ^a   Virtamo, Jarmo ^a   Haukka, Jari K ^a   Aro, Antti ^a   Albanes, Demetrius ^b   Huttunen, Jussi K ^a  

^a ATBC Study   (Finland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alpha tocopherol; Beta carotene; Intermittent claudication; Smoking; Supplementation

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUPPLEMENTATION;

AGED; BETA CAROTENE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; VITAMIN E;

EID: 0345411653     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00176-8     Document Type: Article

References (25)

1. Schroll M., Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chron Dis. 34:1981;261-269.
2. Criqui M.H., Fronek A., Barrett-Conner E., Klauber M.R., Gabriel S., Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 71:1985;510-515.
3. Kannel W.B., McGee D.L. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc. 33:1985;13-18.
4. Shute E.V., Vogelsang A.B., Skelton F.R., Shute W.E. The influence of vitamin E on vascular disease. Surg Gynecol Obstet. 86:1948;1-8.
5. Ratcliffe A.H. Vitamin E in intermittent claudication. Lancet. 2:1949;1128-1130.
6. Livingstone P.D., Jones C. Treatment of intermittent claudication with vitamin E. Lancet. 2:1958;602-604.
7. Hamilton M., Wilson G.M., Armitage P., Boyd J.T. The treatment of intermittent claudication with vitamin E. Lancet. 1:1953;367-370.
8. Williams H.T.G., Clein L.J., Macbeth R.A. Alpha-tocopherol in the treatment of intermittent claudication. Can Med Ass J. 87:1962;538-541.
9. Westheim A.S., Brox D., Selvaag O.A.W. D-alpha-tocopherol ved claudicatio intermittents. Tidsskr Nor Laegerforen. 95:1975;13-15.
10. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherosclerosis. Circulation. 95:1997;1062-1071.
11. Keaney J.F. Jr, Guo Y., Cunningham D., Shwaery G.T., Xu A., Vita J.A. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest. 98:1996;386-394.
12. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics and compliance. Ann Epidemiol. 4:1994;1-9.
13. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1994;1029-1035.
14. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull Who. 27:1962;645-658.
15. Kattermann R., Jaworek D., Möller G. et al. Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem. 22:1984;245-251.
16. Kostner G.M. Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. Clin Chem. 22:1976;695.
17. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 42:1986;121-130.
18. McCullagh P., Nelder J.A. Generalized linear models. 2nd ed:1994;Chapman and Hall, London.
19. Kleijnen J, Mackerras D. Vitamin E for treatment of intemittent claudication. Cochrane Database Systematic Rev 1998;3.
20. Törnwall M.E., Virtamo J., Haukka J.K., Aro A., Albanes D., Edwards B.K., Huttunen J.K. Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication among male smokers. Arterioscler Thromb Vasc Biol. 17:1997;3475-3480. (Erratum, Arterioscler Thromb Vasc Biol 1998;18:1197).
21. Prince M.R., LaMuraglia G.M., MacNichol E.F. Jr Increased preferential absorption in human atherosclerotic plaque with oral beta carotene. Implications for laser endarterectomy. Circulation. 78:1988;338-344.
22. Jonason T., Bergström R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scan. 221:1987;253-260.
23. Leng G.C., Fowkes F.G.R. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol. 45:1992;1101-1109.
24. Fowkes F.G.R., Housley E., Cawood E.H.H., Macintyre C.C.A., Ruckley C.V., Prescott R.J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 20:1991;384-392.
25. Aro S., Koskinen R., Keskimäki I. Sairaalastapoistorekisterin diagnoosi-, toimenpide- ja tapaturmatietojen luotettavuus. Duodecim. 106:1990;1443-1450.